HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment of type II endoleak using Onyx with long-term imaging follow-up.

AbstractPURPOSE:
The purpose of our study is to report our experience with the use of an ethylene vinyl alcohol copolymer (Onyx) in an off-label fashion for the treatment of type II endoleak after endovascular repair of the thoracic (TEVAR) and abdominal (EVAR) aorta.
METHODS:
A retrospective review of patients with type I and/or II endoleak treated with Onyx was performed. Data regarding the technical, clinical, and imaging outcomes were collected. Technical success was defined as decreased or eliminated endoleak on the first imaging follow-up. Clinical success was defined as unchanged or decreased aneurysm sac size on subsequent follow-up.
RESULTS:
Eighteen patients (15 male, 3 female) with a mean age of 79 years (range 69-92) met inclusion criteria (16 abdominal aortic aneurysm, 2 thoracic aortic aneurysm). Sixteen patients had type II endoleak, and 2 had complex type II endoleak with a type I component. The interval between endograft placement and treatment was a mean of 30 months. Direct sac treatment approach was used in 13 patients; transarterial approach was used in 3 patients. Seven patients required the use of coils, N-butyl cyanoacrylate glue, or Amplatzer vascular plugs. The average volume of Onyx used per treatment was 5.6 mL (range 2.5-13). Duration of imaging follow-up was 0.75-72.5 months (mean 32.8). Sixteen of 18 (88.9 %) patients had initial technical and clinical success. Two of 18 patients (11.1 %) were initial technical failures, and 1 remained a failure despite a second treatment and attempted surgical ligation. Eight of 18 (44.4 %) of patients eventually required a second intervention, 5 (27.8 %) of them due to delayed clinical failure. Complications included 1 psoas hematoma, 1 transient L2 nerve paresis, and 1 intraperitoneal Onyx leak; all of these were without clinical sequelae.
CONCLUSION:
Onyx with or without coil/glue/Amplatzer plug embolization is safe and useful in the treatment of type II endoleak after TEVAR and EVAR. However, long-term clinical and imaging follow-up is needed for early detection and management of recurrence of the primary endoleak or the development of new, secondary endoleaks or enlargement of the aneurysm sac.
AuthorsMinhaj S Khaja, Auh Whan Park, Warren Swee, Avery J Evans, J Fritz Angle, Ulku C Turba, Saher S Sabri, Alan H Matsumoto
JournalCardiovascular and interventional radiology (Cardiovasc Intervent Radiol) Vol. 37 Issue 3 Pg. 613-22 (Jun 2014) ISSN: 1432-086X [Electronic] United States
PMID23903786 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cyanoacrylates
  • Onyx copolymer
  • Polyvinyls
  • Dimethyl Sulfoxide
Topics
  • Aged
  • Aged, 80 and over
  • Aortic Aneurysm, Abdominal (surgery)
  • Aortic Aneurysm, Thoracic (surgery)
  • Cyanoacrylates (therapeutic use)
  • Dimethyl Sulfoxide (therapeutic use)
  • Embolization, Therapeutic (methods)
  • Endoleak (therapy)
  • Endovascular Procedures
  • Female
  • Humans
  • Ligation
  • Male
  • Off-Label Use
  • Polyvinyls (therapeutic use)
  • Retreatment
  • Retrospective Studies
  • Septal Occluder Device
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: